Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LSS | P48449 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9851861 | 0.93 | ALDH1A1 (0.51) | KDM4EALDH1A1SMN1; SMN2LSSHRH3 | |
| SCHEMBL1419119 | 0.91 | LTA4H (0.54) | KDM4EALDH1A1HRH3LTA4HCHRNB2 | |
| SCHEMBL1283116 | 0.83 | KDM4E (0.49) | KDM4EHRH3ESR1 | |
| SCHEMBL25274083 | 0.83 | DRD4 (0.44) | KDM4EALDH1A1SMN1; SMN2LTA4HCHRNB2 | |
| SCHEMBL27487618 | 0.82 | FDPS (0.47) | HRH3 | |
| SCHEMBL3160976 | 0.82 | PDK2 (0.47) | KDM4EALDH1A1SMN1; SMN2LTA4HCHRNB2 | |
| SCHEMBL5704638 | 0.81 | KCNA3 (0.42) | KDM4EALDH1A1SMN1; SMN2LTA4H | |
| SCHEMBL131741 | 0.80 | LTA4H (0.53) | ALDH1A1SMN1; SMN2HRH3LTA4HESR1 | |
| SCHEMBL921435 | 0.79 | KCNA3 (0.43) | KDM4EALDH1A1LTA4H | |
| SCHEMBL920281 | 0.79 | CYP1A2 (0.41) | KDM4EALDH1A1SMN1; SMN2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836179-B1 | PIPERIDINE- AND PIPERAZINE-1-CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE (FAAH) FOR THE TREATMENT OF ANXIETY, PAIN AND OTHER CONDITIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-06 | — | — | EP | claimed |
| US-8530476-B2 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-10 | — | — | US | claimed |
| US-20100004261-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-07 | — | — | US | claimed |
| US-7297792-B2 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-20 | — | — | US | claimed |
| EP-1836179-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-26 | — | — | EP | claimed |
| US-20060223800-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS | GARLAND STEPHEN | 2006-10-05 | — | — | US | claimed |
| US-7109199-B2 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | claimed |
| US-20060173184-A1 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-03 | — | — | US | claimed |
| WO-2006074025-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-13 | — | — | WO | claimed |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-29 | — | — | US | claimed |
| EP-1319001-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-18 | — | — | EP | claimed |
| WO-2002024694-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM, P.L.C. (GB) | 2002-03-28 | — | — | WO | claimed |
| EP-0325406-B1 | Diamine compounds | ICI PLC (GB) | 1993-12-29 | — | — | EP | claimed |
| EP-0325406-A2 | Diamine compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-07-26 | — | — | EP | claimed |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2020-04-09 | — | — | US | disclosed |
| US-20180273531-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2018-09-27 | — | — | US | disclosed |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-02-02 | — | — | US | disclosed |
| EP-0325406-B1 | Diamine compounds | ICI PLC (GB) | 1993-12-29 | — | — | EP | disclosed |
| US-5229414-A | Arylacetamide-arylalkylpyrrolidine as hypotensive agents, antiinflammatory agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-07-20 | — | — | US | disclosed |
| EP-0325406-A2 | Diamine compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223800-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS | ADK, PDXK, GPR119 | KDM4E 2081/4885ALDH1A1 462/4885SMN1; SMN2 4363/4885 |
| US-20180273531-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | KDM4E 1105/4885ALDH1A1 709/4885SMN1; SMN2 1532/4885 |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | KDM4E 1105/4885ALDH1A1 709/4885SMN1; SMN2 1532/4885 |
| US-20060173184-A1 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | FAAH, FAAH2, USP47 | KDM4E 704/4885ALDH1A1 1437/4885SMN1; SMN2 1769/4885 |
| US-20100004261-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, USP47 | KDM4E 704/4885ALDH1A1 1437/4885SMN1; SMN2 1769/4885 |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | KDM4E 1105/4885ALDH1A1 709/4885SMN1; SMN2 1532/4885 |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | PDXK, GCK, IAPP | KDM4E 2403/4885ALDH1A1 708/4885SMN1; SMN2 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.